NASDAQ$MIST
Milestone Pharmaceuticals Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for the third quarter and provided a clinical and corporate update.
Milestone Pharmaceuticals reported financial results for the third quarter ended September 30, 2022, and provided a clinical and corporate update. The company is keenly focused on preparations for their planned New Drug Application (NDA), which they expect to submit to the U.S. Food and Drug Administration (FDA) in mid-2023 pending agency feedback.
- Phase 3 RAPID trial of etripamil in patients with PSVT achieved primary efficacy endpoint.
- Safety and tolerability data from repeat dose administration consistent with prior studies utilizing single-dose administration of etripamil.
- Analyses from etripamil Phase 3 PSVT studies featured during Late-Breaking session at AHA Scientific Sessions 2022 demonstrated significant reductions in emergency department utilization for etripamil-treated patients.
- Company plans to submit NDA for etripamil in PSVT to the U.S. FDA in mid-2023 pending Agency feedback
Headline financials
Revenue & EPS history
Milestone Pharmaceuticals · Revenue · Quarterly
$1.5M
Forward guidance
Milestone Pharmaceuticals plans to submit NDA for etripamil in PSVT to the U.S. FDA in mid-2023 pending Agency feedback.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
+2.5%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.5%
Avg return
30 days after
67%
18 / 27 earnings
Positive
+24.1%
Q3 2021
Best reaction
-23.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | — | — | — | |
| Q1 2026 | -9.5% | -23.2% | — | |
| Q3 2025 | +1.0% | +21.5% | +26.2% | |
| Q2 2025 | +7.1% | +9.7% | +23.2% | |
| Q1 2025 | -1.7% | +8.4% | +38.7% | |
| Q4 2024 | +7.9% | -53.7% | -38.9% | |
| Q3 2024 | -5.2% | -12.4% | -4.1% | |
| Q1 2024 | +1.2% | +2.4% | -16.5% | |
| Q4 2023 | +16.0% | +20.7% | +9.3% | |
| Q3 2023 | -23.0% | -24.4% | -13.7% | |
| Q2 2023 | +1.6% | +2.6% | -7.1% | |
| Q1 2023 | +12.8% | +0.5% | +1.3% | |
| Q4 2022 | -4.0% | -0.3% | -9.0% | |
| Q3 2022 | +13.0% | +7.1% | -0.7% | |
| Q2 2022 | +3.6% | +5.3% | +29.2% | |
| Q1 2022 | -2.5% | +1.6% | +1.6% | |
| Q4 2021 | +12.4% | +17.5% | +22.0% | |
| Q3 2021 | +24.1% | +13.9% | +4.5% | |
| Q2 2021 | +0.2% | +2.1% | +7.1% | |
| Q1 2021 | +0.5% | +2.9% | +8.1% | |
| Q4 2020 | -6.6% | -2.4% | -4.2% | |
| Q3 2020 | +6.1% | +6.0% | +19.8% | |
| Q2 2020 | -1.8% | +0.3% | -12.2% | |
| Q1 2020 | +0.3% | +4.8% | +29.5% | |
| Q4 2019 | +7.4% | +8.7% | -90.4% | |
| Q3 2019 | -4.2% | -1.2% | -7.2% | |
| Q2 2019 | +7.8% | +9.9% | +38.1% | |
| Q1 2019 | +3.4% | -4.5% | -16.2% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro